- United States
- /
- Biotech
- /
- NasdaqGM:MRUS
What Are Analysts Expecting From Merus NV. (NASDAQ:MRUS) In The Next Couple Of Years?
Market analysts' prospects for this coming year seems relatively unexciting, with earnings continuing to flop around in the negative territory, reaching -€74.31M in 2019. Furthermore, earnings should fall further in the following year, declining to -€94.99M in 2020 and -€107.02M in 2021.
While it is helpful to be aware of the growth each year relative to today’s value, it may be more valuable to analyze the rate at which the company is moving on average every year. The benefit of this method is that it removes the impact of near term flucuations and accounts for the overarching direction of Merus's earnings trajectory over time, fluctuate up and down. To compute this rate, I put a line of best fit through analyst consensus of forecasted earnings. The slope of this line is the rate of earnings growth, which in this case is -3.98%. This means, we can anticipate Merus will chip away at a rate of -3.98% every year for the next few years.
Next Steps:
For Merus, there are three relevant aspects you should further research:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does MRUS's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of MRUS? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
About NasdaqGM:MRUS
Merus
A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Flawless balance sheet and fair value.
Similar Companies
Market Insights
Community Narratives


